Current Issue : January-March Volume : 2021 Issue Number : 1 Articles : 1 Articles
Failure of antiviral repurposed allopathic drugs and convalescent plasma therapy, vaccines still waiting and with apprehensions of whether they can reach to entire population within reasonably short time and on longevity of immunity it shall develop, already proven failure of physical methods of preventing infection and spread of the COVID-19 and the pandemic-fatigue that has developed in the population in all countries has created a situation of helplessness. It is time for examining the lacunae in approach adopted so far to understand and combat COVID-19. We contemplate that COVID-19 is a simple viral disease with a difference that SARS-CoV-2 is an unusually fast multiplying virus; which rapidly generates Adiponectin deficiency that generates systems failure including pulmonary fibrosis in COVID-19. NK Cell Activity Boosters and Adiponectin Agonist are provided by us. NK Cell Activity Boosters shall counter the factor of fast multiplication rate protecting NK-Cells-Activity-compromised persons either from developing COVID-19 after an infection at its best or at least limiting the disease to mild to moderate stage. For COVID-19 patients, administration of NK cells activity Booster right on the first day of development of symptoms shall provide effective brakes to the multiplication of the virus; and administering Adiponectin Agonist concurrently shall minimize the effect of Adiponectin deficiency; protecting the systems and countering fibrosis in COVID-19 patients, promoting their early recovery; depending on case-to-case, with or without anti-viral medication....
Loading....